{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:54:06Z","timestamp":1790268846188,"version":"4.1.0"},"reference-count":49,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"&quot;Fonds Europ\u00e9en de D\u00e9veloppement R\u00e9gional&quot; and the &quot;Walloon Region&quot;","award":["Operational framework Wallonie-2020.EU. (Tera4all)"],"award-info":[{"award-number":["Operational framework Wallonie-2020.EU. (Tera4all)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>In this work, we are the first to identify thirteen cocrystals of Nefiracetam, a poor water-soluble nootropic compound. Three of which were obtained with the biocompatible cocrystallization agents citric acid, oxalic acid, and zinc chloride. These latter have been fully structurally and physically characterized and the solubility, dissolution rate, and stability were compared to that of the initial Active Pharmaceutical Ingredient (API).<\/jats:p>","DOI":"10.3390\/pharmaceutics12070653","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T09:45:31Z","timestamp":1594374331000},"page":"653","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Improving Nefiracetam Dissolution and Solubility Behavior Using a Cocrystallization Approach"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-7512","authenticated-orcid":false,"given":"Xavier","family":"Buol","sequence":"first","affiliation":[{"name":"Institute of Condensed Matter and Nanosciences, UCLouvain, 1 Place Louis Pasteur, B-1348 Louvain-la-Neuve, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4763-4217","authenticated-orcid":false,"given":"Koen","family":"Robeyns","sequence":"additional","affiliation":[{"name":"Institute of Condensed Matter and Nanosciences, UCLouvain, 1 Place Louis Pasteur, B-1348 Louvain-la-Neuve, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Caro Garrido","sequence":"additional","affiliation":[{"name":"Institute of Condensed Matter and Nanosciences, UCLouvain, 1 Place Louis Pasteur, B-1348 Louvain-la-Neuve, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6898-9036","authenticated-orcid":false,"given":"Nikolay","family":"Tumanov","sequence":"additional","affiliation":[{"name":"Namur Research Institute for Life Sciences (Narilis), Chemistry Department, UNamur, 61 rue de Bruxelles, B-5000 Namur, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Collard","sequence":"additional","affiliation":[{"name":"Institute of Condensed Matter and Nanosciences, UCLouvain, 1 Place Louis Pasteur, B-1348 Louvain-la-Neuve, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Wouters","sequence":"additional","affiliation":[{"name":"Namur Research Institute for Life Sciences (Narilis), Chemistry Department, UNamur, 61 rue de Bruxelles, B-5000 Namur, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-1373","authenticated-orcid":false,"given":"Tom","family":"Leyssens","sequence":"additional","affiliation":[{"name":"Institute of Condensed Matter and Nanosciences, UCLouvain, 1 Place Louis Pasteur, B-1348 Louvain-la-Neuve, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1107\/S1600536806031370","article-title":"N-(2, 6-Dimethylphenyl)-2-(2-oxo-1-pyrrolidin-1-yl) acetamide","volume":"62","author":"Wang","year":"2006","journal-title":"Acta Crystallogr. Sect. E"},{"key":"ref_2","first-page":"788","article-title":"Nefiracetam. Daiichi Seiyaku","volume":"3","author":"Crespi","year":"2002","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1016\/j.xphs.2019.07.010","article-title":"Identifying, Characterizing, and Understanding Nefiracetam in Its Solid State Forms: A Potential Antidementia Drug","volume":"108","author":"Buol","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1039\/C5CC08216A","article-title":"Pharmaceutical cocrystals: Along the path to improved medicines","volume":"52","author":"Duggirala","year":"2016","journal-title":"Chem. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1021\/cg900129f","article-title":"Pharmaceutical cocrystals and their physicochemical properties","volume":"9","author":"Schultheiss","year":"2009","journal-title":"Cryst. Growth Des."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8342","DOI":"10.1039\/C6CC02943D","article-title":"Pharmaceutical cocrystals: Walking the talk","volume":"52","author":"Bolla","year":"2016","journal-title":"Chem. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.drudis.2008.03.004","article-title":"The role of cocrystals in pharmaceutical science","volume":"13","author":"Shan","year":"2008","journal-title":"Drug Discov. Today"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1039\/c4ce00409d","article-title":"Ionic co-crystals of racetams: Solid-state properties enhancement of neutral active pharmaceutical ingredients via addition of Mg2+ and Ca2+ chlorides","volume":"16","author":"Grepioni","year":"2014","journal-title":"CrystEngComm"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1021\/cg3002948","article-title":"Polymorphs, salts, and cocrystals: What\u2019s in a name?","volume":"12","author":"Aitipamula","year":"2012","journal-title":"Cryst. Growth Des."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.drudis.2016.02.001","article-title":"Multidrug co-crystals: Towards the development of effective therapeutic hybrids","volume":"21","author":"Thipparaboina","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1039\/b708112j","article-title":"What is a co-crystal?","volume":"9","author":"Bond","year":"2007","journal-title":"CrystEngComm"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1021\/cg201177p","article-title":"Ionic co-crystals of organic molecules with metal halides: A new prospect in the solid formulation of active pharmaceutical ingredients","volume":"11","author":"Braga","year":"2011","journal-title":"Cryst. Growth Des."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1039\/C8CE00304A","article-title":"Organic\u2013inorganic ionic co-crystals: A new class of multipurpose compounds","volume":"20","author":"Braga","year":"2018","journal-title":"CrystEngComm"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40005-017-0357-1","article-title":"Enhancing solubility of poorly aqueous soluble drugs: Critical appraisal of techniques","volume":"48","author":"Singh","year":"2018","journal-title":"J. Pharm. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijpharm.2012.06.045","article-title":"A new cocrystal and salts of itraconazole: Comparison of solid-state properties, stability and dissolution behavior","volume":"436","author":"Shevchenko","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1517\/17425255.2014.942281","article-title":"Impact of pharmaceutical cocrystals: The effects on drug pharmacokinetics","volume":"10","author":"Shan","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2012.10.043","article-title":"Pharmaceutical cocrystals and poorly soluble drugs","volume":"453","author":"Thakuria","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_18","unstructured":"Leyssens, T., and Harmsen, B. (2020, May 26). WO2019143829-Fasoracetam Crystalline Forms. Available online: https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2019143829."},{"key":"ref_19","unstructured":"Holland, J., Frampton, C., Chorlton, A., and Gooding, D. (2014). Metaxalone Cocrystals. (No. 8,871,793), U.S. Patent."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1007\/s11095-006-9032-3","article-title":"Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API","volume":"23","author":"McNamara","year":"2006","journal-title":"Pharm. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/bs.podrm.2018.11.004","article-title":"Cocrystal Systems of Pharmaceutical Interest: 2012\u20132014","volume":"44","author":"Brittain","year":"2019","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1021\/cg201510n","article-title":"Cocrystal systems of pharmaceutical interest: 2010","volume":"12","author":"Brittain","year":"2012","journal-title":"Cryst. Growth Des."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.1021\/cg301114f","article-title":"Cocrystal systems of pharmaceutical interest: 2011","volume":"12","author":"Brittain","year":"2012","journal-title":"Cryst. Growth Des."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1039\/B815174A","article-title":"The role of solvent in mechanochemical and sonochemical cocrystal formation: A solubility-based approach for predicting cocrystallisation outcome","volume":"11","author":"Childs","year":"2009","journal-title":"CrystEngComm"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1021\/acs.cgd.5b01776","article-title":"Polymorphism of mechanochemically synthesized cocrystals: A case study","volume":"16","author":"Fischer","year":"2016","journal-title":"Cryst. Growth Des."},{"key":"ref_26","unstructured":"Rigaku, O.D. (2015). CrysAlisPro Software System, Rigaku Coorporation. Version 1.171. 38.41 l."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053229614024218","article-title":"Crystal structure refinement with SHELXL","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr. Sect. C"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1107\/S090744490804362X","article-title":"Structure validation in chemical crystallography","volume":"65","author":"Spek","year":"2009","journal-title":"Acta Crystallogr. Sect. D"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1107\/S0021889807067908","article-title":"Mercury CSD 2.0\u2013new features for the visualization and investigation of crystal structures","volume":"41","author":"Macrae","year":"2008","journal-title":"J. Appl. Crystallogr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.addr.2007.05.011","article-title":"Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates","volume":"59","author":"Blagden","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/anie.199523111","article-title":"Supramolecular synthons in crystal engineering\u2014A new organic synthesis","volume":"34","author":"Desiraju","year":"1995","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1039\/C1CS15171A","article-title":"Mechanochemistry: Opportunities for new and cleaner synthesis","volume":"41","author":"James","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1021\/cg500588t","article-title":"Cocrystal formation between chiral compounds: How cocrystals differ from salts","volume":"14","author":"Springuel","year":"2014","journal-title":"Cryst. Growth Des."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1021\/cg201291k","article-title":"Advances in pharmaceutical co-crystal screening: Effective co-crystal screening through structural resemblance","volume":"12","author":"Springuel","year":"2012","journal-title":"Cryst. Growth Des."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1021\/acs.cgd.9b00136","article-title":"Ionic cocrystals of etiracetam and levetiracetam: The importance of chirality for ionic cocrystals","volume":"19","author":"Song","year":"2019","journal-title":"Cryst. Growth Des."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Shemchuk, O., Song, L., Tumanov, N., Wouters, J., Braga, D., Grepioni, F., and Leyssens, T. (2020). Chiral resolution of RS-oxiracetam upon cocrystallization with pharmaceutically acceptable inorganic salts. Cryst. Growth Des.","DOI":"10.1021\/acs.cgd.9b01725"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1021\/cg701022e","article-title":"Polymorphism in carbamazepine cocrystals","volume":"8","author":"Elie","year":"2008","journal-title":"Cryst. Growth Des."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1021\/cg201581z","article-title":"Importance of solvent selection for stoichiometrically diverse cocrystal systems: Caffeine\/maleic acid 1: 1 and 2: 1 cocrystals","volume":"12","author":"Leyssens","year":"2012","journal-title":"Cryst. Growth Des."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1107\/S0108768189012929","article-title":"Graph-set analysis of hydrogen-bond patterns in organic crystals","volume":"46","author":"Etter","year":"1990","journal-title":"Acta Crystallogr. Sect. B"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/anie.199515551","article-title":"Patterns in hydrogen bonding: Functionality and graph set analysis in crystals","volume":"34","author":"Bernstein","year":"1995","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_41","unstructured":"(2020, May 26). Oxalic Acid-Registration Dossier-ECHA. Available online: https:\/\/echa.europa.eu\/registration-dossier\/-\/registered-dossier\/14786\/4\/3."},{"key":"ref_42","unstructured":"(2020, May 26). United States Department of Labor-Occupational Safety and Health Administration-Oxalic Acid, Available online: https:\/\/www.osha.gov\/chemicaldata\/chemResult.html?RecNo=270."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1039\/b709260c","article-title":"Survival of the fittest polymorph: How fast nucleater can lose to fast grower","volume":"9","author":"Yu","year":"2007","journal-title":"CrystEngComm"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1021\/acs.cgd.8b00254","article-title":"Cross-nucleation between polymorphs: Quantitative modeling of kinetics and morphology","volume":"18","author":"Looijmans","year":"2018","journal-title":"Cryst. Growth Des."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0040-6031(86)87081-2","article-title":"Thermal decomposition of citric acid","volume":"98","author":"Barbooti","year":"1986","journal-title":"Thermochim. Acta"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pcrysgrow.2016.07.001","article-title":"Spring and parachute: How cocrystals enhance solubility","volume":"62","author":"Bavishi","year":"2016","journal-title":"Prog. Cryst. Growth Charact. Mater."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/jps.20906","article-title":"Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations","volume":"96","author":"Tawa","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7228","DOI":"10.1021\/acs.cgd.8b01200","article-title":"Estimation of the Solubility of Metastable Polymorphs: A Critical Review","volume":"18","author":"Nicoud","year":"2018","journal-title":"Cryst. Growth Des."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1039\/C8CE01428K","article-title":"Polymorph control in batch seeded crystallizers. A case study with paracetamol","volume":"21","author":"Nicoud","year":"2019","journal-title":"CrystEngComm"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/7\/653\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:49:34Z","timestamp":1760176174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/7\/653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["pharmaceutics12070653"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics12070653","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,9]]}}}